Michael Heffernan is the Founder and Chairman of the Board of Collegium Pharmaceutical. Mike served as President and Chief Executive Officer (CEO) of Collegium Pharmaceutical until June 2018. He has more than 25 years of experience in the pharmaceutical and related healthcare industries. Mr. Heffernan previously founded and served as President and CEO of Onset Dermatologics, a dermatology-focused company that was spun out of Collegium to create PreCision Dermatology (acquired by Valeant). Mr. Heffernan also previously co-founded and served as President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization acquired by PhyMatrix Corp, and he subsequently served as President and CEO of PhyMatrix. Mr. Heffernan began his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been an advisor and Investor in a number of healthcare companies. His past board memberships include: TyRx (acquired by Medtronic), Cornerstone Therapeutics (acquired by Chiesi), Ocata (acquired by Astellas) and PreCision Dermatology. Mr. Heffernan currently serves as the Chairman of the Board for Veloxis Pharmaceuticals and as Director of the Board for Keryx Biopharmaceuticals, Inc. He earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.